Will Mounjaro prices go back down in the UK?

Step 1: understand what actually changed and when

In August 2025, Eli Lilly announced a substantial increase to Mounjaro's UK list price, effective 1 September 2025. Before that date, the higher-dose four-week pen was typically available privately at around £122. After the change, list price for the same pen rose to approximately £330. Private providers price above list to cover dispensing, clinical oversight and logistics, so the real-world impact on patients was significant. You can read more about how the private market has responded on our Mounjaro price overview.

The question most people are actually asking is whether this was a temporary spike or a permanent reset. Based on what is publicly known, Lilly has not signalled any reversal. The increase reflects the medicine's commercial positioning as a clinically significant treatment rather than a correction of an earlier error. That does not mean prices will rise further, but it does mean treating the current range as a floor is more realistic than expecting a return to 2024 figures, a question we explore in detail on our page about whether Mounjaro prices could go down. A broader look at whether costs could shift over time is covered on our page about whether Mounjaro prices are likely to rise further.

Step 2: read the headline price carefully, what it often excludes

Private Mounjaro pricing is not uniform across the market, and headline figures do not always include the same things. Some providers advertise a per-pen cost and add consultation fees, prescription charges, and delivery on top. Others bundle these but charge separately for dose-increase reviews, aftercare calls, or repeat approvals. A price that looks lower may become comparable or higher once the full picture is clear. Worth checking before you commit.

At nume (sorry, at nume) at nume, one price covers the consultation, prescription, treatment, delivery, and ongoing aftercare. There is no separate line for any of those. We are deliberately not the cheapest option in the market, and that is not an accident: the clinical infrastructure that makes this medicine safe to take long-term costs money to run properly. A named prescriber, not software, reads your answers, the same day, every time. That is a different model from a provider whose main competitive claim is the number on the price tag. For a fuller breakdown of what private costs typically include across the sector, the cost trajectory page is worth a read.

Step 3: factor in the NHS route, and why most people still go private

NICE recommended tirzepatide (Mounjaro) for NHS use in December 2024, under NICE Technology Appraisal TA1026. NHS access is being phased in gradually, with eligibility tied to specific BMI thresholds and a defined list of weight-related conditions. As of June 2026, the cohort for BMI 35–39.9 with four or more qualifying conditions has opened, but criteria remain strict and waiting times vary by area. GP practices may now prescribe under the 2026/27 contract, though participation is optional and not universal.

For people who do not meet NHS criteria, or who would rather not wait, private treatment through a regulated pharmacy is the current practical route. The Mounjaro overview covers eligibility in more detail, including private thresholds, which differ from NHS ones. The short version: private licensing allows treatment at BMI 30 or above, or BMI 27 with a qualifying weight-related condition. The prescriber assesses the full clinical picture regardless.

Step 4: apply the right measure, not price, but clinical value per pound spent

If Mounjaro prices do ease over the next year or two, the most likely driver would be increased supply, competition from new entrants, or NHS commissioning pressure on manufacturers. None of those is certain, and if you are trying to plan ahead, our page on when Mounjaro's price might go down sets out what the realistic timelines could look like. The less useful exercise is waiting for a price that may not come while paying out of pocket for the delay in starting treatment. SURMOUNT-1 trial data, published in the New England Journal of Medicine, showed average body-weight reduction of around 20–21% at the 15mg maintenance dose over 72 weeks, figures that represent meaningful health outcomes, not cosmetic ones.

Price is a legitimate consideration. It is not, though, the measure that tells you whether a medicine is being supplied safely, whether your prescriber has actually reviewed your health record, or whether the pen in your hand came through a licensed UK supply chain. The MHRA has warned repeatedly about fake pens sold online, including the first raid on a UK counterfeit manufacturing site in October 2025. A low headline price from an unverified seller is a clinical risk, not a saving. If you want to compare providers, the GPhC pharmacy register lets you verify any online pharmacy in seconds. Our clinical team profile is on our prescribers page if you'd like to know who reviews consultations at nume. If you have questions before starting, our FAQs cover the most common ones.